| dc.contributor | 科管智財所 | |
| dc.creator (作者) | 陳秉訓 | |
| dc.creator (作者) | Chen, Ping-Hsun | |
| dc.date (日期) | 2022-10 | |
| dc.date.accessioned | 29-May-2023 09:31:15 (UTC+8) | - |
| dc.date.available | 29-May-2023 09:31:15 (UTC+8) | - |
| dc.date.issued (上傳時間) | 29-May-2023 09:31:15 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/144872 | - |
| dc.format.extent | 106 bytes | - |
| dc.format.mimetype | text/html | - |
| dc.relation (關聯) | Biotechnology Law Report, Vol.41, No.5, pp.240-250 | |
| dc.title (題名) | How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement—A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. | |
| dc.type (資料類型) | article | |
| dc.identifier.doi (DOI) | 10.1089/blr.2022.29285.phc | |
| dc.doi.uri (DOI) | https://doi.org/10.1089/blr.2022.29285.phc | |
